文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

基于治疗药物监测的多黏菌素B治疗碳青霉烯类耐药菌脓毒症:PMB-CROS随机临床试验

Polymyxin B therapy based on therapeutic drug monitoring in carbapenem-resistant organisms sepsis: the PMB-CROS randomized clinical trial.
PubMed 文献 · Crit Care · 2023-06-13
一句话结论在碳青霉烯类耐药革兰阴性菌脓毒症中,多黏菌素B高剂量方案(负荷150 mg、维持75 mg每12小时)安全且改善长期生存,但14天临床反应无显著差异。

该多中心随机对照试验纳入中国河南省26家医院311例碳青霉烯类耐药革兰阴性菌(CR-GNB)脓毒症患者,随机分为高剂量组(负荷150 mg、维持75 mg每12小时)与低剂量组(负荷100 mg、维持50 mg每12小时),均以治疗药物监测(TDM)指导调整,目标稳态24小时AUC(ssAUC0-24)为50–100 mg·h/L。意向性分析显示14天临床反应无显著差异(高剂量组62.5% vs 低剂量组59.7%,p=0.527)。高剂量组更多患者达到目标ssAUC0-24(63.8% vs 38.9%,p=0.005),Kaplan-Meier 180天生存曲线显示高剂量组生存优势(p=0.037)。目标AUC达标与临床结局无关,但与急性肾损伤(AKI)相关(p=0.019);两组不良事件无差异。

要点

  • 高剂量方案为负荷150 mg、维持75 mg每12小时,低剂量方案为负荷100 mg、维持50 mg每12小时,均经TDM按ssAUC0-24 50–100 mg·h/L调整。
  • 14天临床反应高剂量组95/152(62.5%)vs 低剂量组95/159(59.7%),差异无统计学意义(p=0.527)。
  • 达到目标ssAUC0-24者高剂量组63.8% vs 低剂量组38.9%(p=0.005);脓毒性休克亚组达标率更高(高剂量组71.4% vs 全体63.8%,p=0.037;低剂量组58.3% vs 全体38.9%,p=0.0005)。
  • Kaplan-Meier 180天生存曲线显示高剂量组较低剂量组有生存优势(p=0.037)。
  • 目标AUC达标与临床结局无关,但与AKI相关(p=0.019);两组不良事件无差异。

适用人群与场景

  • 中国河南省26家医院收治的碳聚霉烯类耐药革兰阴性菌(CR-GNB)所致脓毒症、且对多黏菌素B敏感的患者。
  • 共纳入311例,高剂量组152例,低剂量组159例。

诊断标准与关键阈值

  • 目标稳态24小时AUC(ssAUC0-24)为50–100 mg·h/L,由治疗药物监测(TDM)测定并据此判断是否需调整多黏菌素B剂量。

处置流程与药物剂量

  • 高剂量组:多黏菌素B负荷剂量150 mg,维持剂量75 mg每12小时。
  • 低剂量组:多黏菌素B负荷剂量100 mg,维持剂量50 mg每12小时。
  • 两组均采用TDM,根据ssAUC0-24是否处于50–100 mg·h/L决定剂量调整。

研究设计与关键结果

  • 研究类型:随机对照试验,26家医院参与,纳入311例CR-GNB脓毒症患者,高剂量组152例、低剂量组159例。
  • 主要终点:14天临床反应意向性分析无显著差异,高剂量组95/152(62.5%)vs 低剂量组95/159(59.7%),p=0.527。
  • 关键次要终点:Kaplan-Meier 180天生存曲线显示高剂量组较低剂量组有生存优势(p=0.037)。
  • 达标率:达到目标ssAUC0-24者高剂量组63.8% vs 低剂量组38.9%(p=0.005);脓毒性休克亚组高剂量组71.4% vs 全体高剂量组63.8%(p=0.037),低剂量组58.3% vs 全体低剂量组38.9%(p=0.0005)。
  • 目标AUC达标与临床结局无关,但与急性肾损伤(AKI)相关(p=0.019);高剂量组与低剂量组不良事件无差异。

证据类型、等级与局限

  • 证据类型:随机对照试验(RCT)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,固定多黏菌素B负荷剂量150 mg、维持剂量75 mg每12小时对CR-GNB所致脓毒症患者安全,并改善长期生存。
  • AUC升高与AKI发生率增加相关,作者认为TDM结果有助于预防AKI。

指南或共识出处

  • PMB-CROS随机临床试验,中国河南省26家医院参与,注册号ChiCTR2100043208,注册日期2021年1月26日。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The appropriate administration regimen of polymyxin B is yet controversial. The present study aimed to explore the optimal dose of polymyxin B under therapeutic drug monitoring (TDM) guidance.

METHODS: In China's Henan province, 26 hospitals participated in a randomized controlled trial. We included patients with sepsis caused by carbapenem-resistant Gram-negative bacteria (CR-GNB) susceptible to polymyxin B. The patients were randomly divided into a high-dose (HD) group or a low-dose (LD) group and received 150 mg loading dose, 75 mg every 12 h and 100 mg loading dose, 50 mg every 12 h, respectively. TDM was employed to determine if the dose of polymyxin B needs adjustment based on the area under the concentration-time curve across 24 h at a steady state (ssAUC0-24) of 50-100 mg h/L. The primary outcome was the 14-day clinical response, and the secondary outcomes included 28- and 14-day mortality.

RESULTS: This trial included 311 patients, with 152 assigned to the HD group and 159 assigned to the LD group. Intention-to-treat analysis showed that the 14-day clinical response was non-significant (p = 0.527): 95/152 (62.5%) in the HD group and 95/159 (59.7%) in the LD group. Kaplan-Meier's 180-day survival curve showed survival advantage in the HD group than in the LD group (p = 0.037). More patients achieved the target ssAUC0-24 in the HD than in the LD group (63.8% vs. 38.9%; p = 0.005) and in the septic shock subgroup compared to all subjects (HD group: 71.4% vs. 63.8%, p = 0.037; LD group: 58.3% vs. 38.9%, p = 0.0005). Also, the target AUC compliance was not correlated with clinical outcomes but with acute kidney injury (AKI) (p = 0.019). Adverse events did not differ between the HD and LD groups.

CONCLUSION: A fixed polymyxin B loading dose of 150 mg and a maintenance dose of 75 mg every 12 h was safe for patients with sepsis caused by CR-GNB and improves long-term survival. The increased AUC was associated with increased incidence of AKI, and TDM results were valued to prevent AKI. Trial registration Trial registration ClinicalTrials.gov: ChiCTR2100043208, Registration date: January 26, 2021.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Liu S, Wu Y, Qi S, et al. Polymyxin B therapy based on therapeutic drug monitoring in carbapenem-resistant organisms sepsis: the PMB-CROS randomized clinical trial. Crit Care. 2023. PMID: 37312218. doi:10.1186/s13054-023-04522-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。